Regeneron Reports Phase 3 Results for Dupixent in Peanut Allergy

Regeneron and Sanofi today announced Phase 3 trial results for Dupixent (dupilumab) in adults and adolescents with peanut allergy. The trial demonstrated that Dupixent significantly increased the threshold dose of peanut protein that patients could tolerate without allergic reaction, with 58% of patients in the Dupixent arm tolerating at least 1000 mg of peanut protein compared to 2% in the placebo arm.